INZY
Inozyme Pharma
INZY
INZY
Delisted
INZY was delisted on the 30th of June, 2025.
74 hedge funds and large institutions have $190M invested in Inozyme Pharma in 2023 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
4% more capital invested
Capital invested by funds: $183M → $190M (+$6.85M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
52% less call options, than puts
Call options by funds: $126K | Put options by funds: $263K
Holders
74
Holding in Top 10
1
Calls
$126K
Puts
$263K
Top Buyers
| 1 | +$8.29M | |
| 2 | +$2.87M | |
| 3 | +$2.58M | |
| 4 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
+$2.49M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.1M |
Top Sellers
| 1 | -$8.95M | |
| 2 | -$3.62M | |
| 3 | -$3.61M | |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$2.89M |
| 5 |
CA
CHI Advisors
New York
|
-$820K |